Fig. 2: C2/C1 ctDNA assessment for tumor-informed maxVAF and MR scores. | Nature Medicine

Fig. 2: C2/C1 ctDNA assessment for tumor-informed maxVAF and MR scores.

From: Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

Fig. 2

a, Overall C2/C1 tumor-informed maxVAF (pembrolizumab, n = 87; chemotherapy, n = 102) and MR score changes (pembrolizumab, n = 89; chemotherapy, n = 89) by treatment arm. b, Patient-level C2/C1 tumor-informed maxVAF changes (pembrolizumab, n = 87; chemotherapy, n = 102) by response status, BOR and treatment arm. c, MR score changes (pembrolizumab, n = 89; chemotherapy, n = 89) by response status, BOR and treatment arm. d,e, C2/C1 tumor-informed maxVAF ratio (d) and best 9-week percentage change (e) from baseline in tumor size for the pembrolizumab and the chemotherapy arms. In a–c, the center line corresponds to the median and the box is delineated by first and third quartiles. Whiskers extend to any points within 1.5 times the interquartile range, with points lying beyond identified individually as potential outliers. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Back to article page